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Background and Aims: ALPPS (associating liver partition and portal vein ligation
for staged hepatectomy), a novel 2-staged hepatectomy, dramatically accelerates liver
regeneration and thus enables extensive liver tumor resection. The signaling networks
underlying the ALPPS-induced accelerated regeneration process are largely unknown.
Methods: We performed transcriptome profiling (TP) of liver tissue obtained from a
mouse model of ALPPS, standard hepatectomy (68% model), and additional control
surgeries (sham, PVL and Tx). We also performed TP using human liver biopsies (n = 5)
taken from the occluded lobe and the future liver remnant (FLR) during the first step of
ALPPS surgery (4–5 h apart). We used Oncofinder computational tools, which covers
378 ISPs, for unsupervised, unbiased quantification of ISP activity.
Results: Gene expression cluster analysis revealed an ALPPS specific signature: the
IGF1R Signaling Pathway (Cell survival), the ILK Pathway (Induced cell proliferation),
and the IL-10 Pathway (Stability determination) were significantly enriched, whereas
the activity of the Interferon Pathway (Transcription) was reduced (p < 0.05). Further,
the PAK- and ILK-associated ISPs were activated at an earlier time point, reflecting
significant acceleration of liver regeneration (p < 0.001). These pathways, which were
also recovered in human liver biopsies, control cell growth and proliferation, inflammatory
response, and hypoxia-related processes.
Conclusions: ALPPS is not a straightforward addition of portal vein ligation (PVL) plus
transection—it is more. The early stages of normal and accelerated liver regeneration are
clearly discernible by a significantly increased and earlier activation of a small number of
signaling pathways. Compounds mimicking these responses may help to improve the
ALPPS method and further reduce the hospitalization time of the patient.
Keywords: two-staged hepatectomy, ALPPS, transcriptome profiling, signaling pathways, Oncofinder
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INTRODUCTION
Liver regeneration is controlled by a cooperating, redundant
system of biological networks performing an assortment of tasks,
which together result in a coordinated response to replenish
lost liver tissue. The regenerating capacity of the liver inspired
liver surgeons to develop 2-staged strategies to perform extended
liver resections to clean the organ from multiple tumors. In the
conventional 2-staged strategies, the complete restoration of a
functional liver may take up to 8–10 weeks (1, 2). Recently,
a novel two-staged strategy has been introduced: ALPPS (for:
Associating Liver Partition and Portal vein ligation for Staged
hepatectomy) (3). In the first stage of the ALPPS procedure, the
portal vein is ligated, followed by removal of any tumor in the
future liver and an in situ split of the parenchyma between the
healthy and diseased liver (partition or transection) is performed.
In the second step, the isolated, deportalized liver is removed,
leaving behind a tumor-free, hypertrophic liver remnant (4–
6). The main advantage of the ALPPS strategy is that the
accelerated regeneration of the liver remnant, which reaches
a body-sustaining size within 7–10 days, enables the prompt
elimination of the major tumor load (4, 7).
The biological processes underlying liver regeneration
processes are complex. They involve (thyroid) hormones (8),
cytokines [IL-6 (9) and TNF (10)], growth factor responses [HGF,
TGF-β, epidermal growth factor (EGF)] (11, 12), glucose- and
bile acid metabolism (13, 14), and platelet-derived factors, such
as serotonin (15). Further studies in knockout mouse models
revealed several key switches in signal-transduction systems,
which either delay or accelerate the regenerating process. NF-κB
(16), nuclear receptors [FXR (14) and CAR (17)] have been
described as accelerators, whereas p21 (18), Socs3 (19), and Tob1
(20) act as repressors.
Recently, we reported that that Indian hedgehog (Ihh), a
secreted ligand important for fetal development, is a crucial
mediator of the regenerative acceleration triggered by ALPPS
surgery (21). Despite our increasing knowledge of the interwoven
biological signaling networks underlying normal and accelerated
liver regeneration, comprehensive whole genome analyses are
required for full recognition of the underlying pathways.
The newly developed bioinformatics tool OncoFinder enables
quantitative measurement of intracellular signaling pathway
(ISP) activation based on whole genome expression data (22,
23). The advantage of OncoFinder over alternative tools, such
as Metacore and Ingenuity Pathway Analysis (IPA), is that
it quantifies the pathway activation strength (PAS) (22–24).
PAS values represent the cumulative value of perturbations
in a signaling pathway and serve as reliable indicators of
pathological changes to the intracellular signaling machinery.
The PAS value itself serves as a robust new biomarker that can
distinguish between the pathway activation profiles in different
tissues (23, 25).
Abbreviations: ALPPS, Associating Liver Partition and Portal Vein Ligation
Surgery; LLLx, left lateral lobe resection; PAS, pathway activation strength; PVL,
portal vein ligation; Tx, parenchymal transection; TSH, two-stage hepatectomy;
FLR, functional liver remnant.
The aim of our present study was to assess comprehensively
the ISPs underlying normal and accelerated liver regeneration
in two established mouse models (26, 27), and in liver tissue
obtained from humans before and after the first step of ALPPS
surgery. The data designate that our murine ALPPS model—
despite differences—reflects ALPPS-induced accelerated liver
regeneration in humans.
METHODS
Surgery
ALPPS surgery in C57BL/6 mice (n = 3 for all procedures)
was performed as described earlier (26). In brief, a 90% PVL
was performed, leaving a 10% functional remnant consisting of
the left and a part of the right middle lobe. Then, a partial
80% transection was done through the middle lobe along the
demarcation line of the occluded/non-occluded parenchyma.
The left lateral lobe (LLL, 25% of liver volume) was also resected
to simulate the cleaning of the liver from smaller tumors as
often carried out in human ALPPS (21, 26). ALPPS surgery is
associated with some initial injury (serum ALT at around 5,000
U/I 1 day post-operation), which however declines over time
toward zero at day 7 post-operation. Serum HMGB1, released
by necrotic cells, is not elevated at any time post-operation,
indicating the absence of significant necrosis as confirmed by
histology on day 2. Very similar findings are observed for PVL
surgery, indicating that ALPPS does not augment injury (26).
Following 68% hepatectomy, injury is negligible, with ALT<100
U/I 1 day post-operation (27). Serum bilirubin is not elevated
following ALPPS, PVL, or 68% hepatectomy (26, 27). Liver
weight gain is clearly evident already at 4 h post ALPPS, steeply
rising to reach a plateau at 24 h (with step 2—resection of ligated
parts—usually performed at day 2 in mice). PVL also induces—
to a lesser extent—early liver weight gain; however, a low plateau
is reached already at 8 h post PVL (21). After 68% hepatectomy,
liver starts to gain weight more slowly, with its strongest gains
toward 48 h. This time point coincides with the hepatocellular
mitotic peak, which follows cell cycle entry around 16–20 h post
68% hepatectomy (27). In contrast, hepatocytes enter the cell
cycle already at 4 h post ALPPS, with a first mitotic peak at 8 h.
After PVL, cell cycle entry also occurs early, but only at levels
similar to transection (which does not induce regeneration), and
low numbers of mitoses are observed from 12 h onwards (21).
Therefore, ALPPS surgery accelerates mouse liver regeneration
both in time and magnitude relative to other liver surgeries.
Standard hepatectomy (partial 68% hepatectomy) in mice
was performed as described by Lehmann (27). In short, a
midline incision was performed, and the liver was freed from
ligaments. The pedicle of the left lobe was ligated (silk, 6/0)
and resected. After cholecystectomy (Prolene, 8/0; Ethicon,
Neuchatel, Switzerland), the middle lobe was ligated in 2 steps
(silk 6/0) and resected. All animal experiments conformed to
the Swiss Federal Animal Regulations and were approved by the
Veterinary Office of Zurich. Animals aged 10–12 weeks were
kept on a 12-h day/night cycle with free access to food and
water. C57BL/6 mice were obtained from Envigo (Horst, The
Netherlands). All animals were part of the same shipment, same
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age and gender, randomized, and part of the same project to
ensure similar conditions.
Tissue Specimen
Mice liver tissue was collected at different time points after
surgery (as indicated throughout the manuscript). Human liver
tissue specimens (biopsies) were obtained from the Department
of Visceral and Transplant Surgery, University Hospital Zurich
with the approval of the local ethics committees (Nr: 2015-
0547, Cantonal Ethics Committee, Zurich) and written consent
of all patients (for characteristics see Supplementary Data S-XI).
After laparotomy and initial inspection of the abdomen, liver
punch biopsies were taken of the future liver remnant (FLR)
immediately before starting ALPPS step 1 [biopsy 1]. Then,
partial ALPPS was performed as described earlier (7). Biopsy
2 was taken of the FLR immediately before closure of the
laparotomy [end of ALPPS step 1]. All biopsies were snap frozen
in liquid nitrogen and stored at −80◦C. RNA isolation and
sequencing was performed as described below.
RNA Isolation and Sequencing
RNA isolation was performed using the TRIzol Method as
described by the manufacturers (Life Technologies, Switzerland).
An equimolar RNA pool was prepared from liver tissue and/or
biopsies using DNA Column Clean-up (Qiagen, Basel, CH).
Then, 1 µg of total RNA was used for library preparation
according to the Illumina TruSeq stranded mRNA sample
preparation protocol (Illumina). The resultingmRNA library was
sequenced on an Illumina Hiseq 2,500 sequencer (Functional
Genomics Center Zürich, Zürich, CH). Sequenced reads were
aligned to the mouse and human (hg19) reference genome with
TopHat (version 2.0.10) 27 by using the -G (GTF file of Ensembl
release 75) option. Furthermore, the aligned reads were used
to quantify mRNA expression by using HTSeq-count (version
0.6.1)28 with hg19 GTF (Ensembl release 75). All data have been
deposited to the European Nucleotide Archive (ENA) under the
accession code PRJEB15593.
Differential Expression Analysis
Raw reads were filtered by quality >30 score through FASTX
toolkit and then trimmed at 5
′
and 3
′
in order to remove
index and adapter. Only the remaining reads were used for
alignment with the human genome assembly (GRCh37), where
we employed TopHat v2.0.14 (28).
Source Datasets
The signaling pathways knowledge base developed by
SABiosciences (https://www.slideshare.net/elsavonlicy/pathway-
mapreferenceguide) was used to determine structures of
intracellular pathways for OncoFinder (22, 23).
Functional Annotation of Gene Expression
Data
For the functional annotation of the primary gene expression
data, we applied our original algorithm termed OncoFinder
(22, 23). It enables calculation of the Pathway Activation Strength
(PAS), a value that serves as a qualitative measure of pathway
activation. Briefly, the algorithm utilizes the following formula
to evaluate pathway activation:
PASp =
∑
n
ARRnp · BTIFn · lg (CNRn) (1)
Here the case-to-normal ratio, CNRn, is the ratio of expression
levels for a given gene (n) in the sample to the mean value for
the control group. The Boolean flag of BTIF (beyond tolerance
interval flag) equals to zero when the CNR value has passed
simultaneously the two criteria that demark the significantly
perturbed expression level from essentially normal. First, the
expression level for the sample lies within the tolerance interval,
where p > 0.05. Second, the value of CNR differs from 1
considerably, CNR 0.66 or CNR 1.5. The discrete value of ARR
(activator / repressor role) reflects the functional role of a protein
n in the pathway (22). The pathway-specific PAS values calculated
by Oncofinder are more reliable than single gene analysis
and improves the robustness of experimental transcriptomics
data (23).
Statistical Tests
The PAS values for each normal sample were obtained using the
whole set of these normal samples as a reference. Distribution
of PAS values was estimated, assuming its Gaussian behavior.
Then, for each pathway of each sample, the probability that its
PAS value comes from this estimated distribution was calculated.
Additionally, p-values for each pathway of the entire group of
samples were calculated usingWilcoxon rank-sum test. Principal
component analyses were performed using the MADE4 package
(29). Hierarchical clustering heatmaps with Pearson distance
and average linkage were generated using heatmap.2 function
from “gplots” package (30). Pearson tau correlation matrices
were calculated in R 3.1.1 using a function of standard library
“cor” with the default settings. Correlation diagrams were built
using a function “corrplot” from the package “corrplot” sorted
with respect to hierarchical clustering. Similarities between
the pathways according to the content of similar genes were
calculated using the Jaccard coefficient. The Jaccard coefficient
measures similarity between finite sample sets and is defined as
the size of the intersection divided by the size of the union of
the sample sets. Venn diagrams were constructed using Venny
2.1 [http://bioinfogp.cnb.csic.es/tools/venny/].
miRNA Target Prediction
Focusing on differentially expressed pre-miRNAs present in our
datasets, we predicted their putative mRNA targets considering
only experimentally validated miRNA-mRNA interactions using
the Ingenuity Pathway Analysis (IPA) suite (Qiagen, Redwood
City, Calif; https://www.slideshare.net/elsavonlicy/pathway-
mapreferenceguide). We used miRTarBase for predicting targets
of miRNAs and assessed the influence of miRNAs on ISPs
using our method MiRImpact (31). Among all miRNA-targeted
mRNAs, only genes having at least 10 reads (read count ≥10)
were considered true targets for differentially expressed miRNAs
in BSM cells.
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FIGURE 1 | Venn diagrams showing the total of unique and common ISPs after 68% hepatectomy and ALPPS surgery. (A) Unique and common ISPs
activated/repressed 4 h after surgery. (B) Common ISPs activated/repressed 8 h after surgery (For details see: Table 2). (C) Per-sample enrichment scores for genes
involved in the G1/S transition phase of the mitotic cell cycle (the GO_BP_MM_G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE signature from the GSKB database),
calculated using gene set variation analysis (GSVA). (D) Cyclin E1 mRNA (Ccne1) mRNA expression. (E) Expression of p21 mRNA after ALPPS and 68% hepatectomy
(as indicated); *p < 0.005.
Gene Set Variation Analysis of Mitotic Cell
Cycle Signatures
To compare the kinetics of the expression of mitotic cell
cycle genes between ALPPS and standard hepatectomy, gene
signatures for different phases of the mitotic cell cycle were
selected from the MSigDB and GSKB online databases. For
access to the GSKB database, the gskb R package (version 1.10.0)
was used. Individual-sample gene set enrichment scores were
calculated using Gene Set Variation Analysis with the GSVA R
package, version 1.26.0. All gene set enrichment analyses were
performed within the R statistical programming environment,
version 3.4.3.
RESULTS
ALPPS Surgery Induced an Earlier Cell
Cycle Entry
To elucidate the molecular pathways responsible for accelerated
liver regeneration, hepatic RNA isolated at several time points
after ALPPS, PVL, transection, LLLx, and sham operation
was deep-sequenced. Pathway activation strength (PAS) profiles
were established using the normalized gene expression levels
of liver-expressed genes with the OncoFinder algorithm.
First, we analyzed the activation status of 378 ISPs. Using
the PAS values, we built hierarchical clustering heat maps
with Euclidean distance and average linkage for all groups
(For heatmaps see: Supplementary Data S-I). We identified
the common and unique ISPs for ALPPS and normal liver
regeneration as induced by standard hepatectomy. As shown
in Figure 1A, 160 and 72 ISPs were significantly affected
4 h after 68% hepatectomy and ALPPS, respectively. While
89 ISPs were unique for standard hepatectomy, only the
Interferon main pathway was specific for the ALPPS procedure
(PAS:−0.479740209). Likewise, 120 ISPs were shared between
the two procedures, with no unique ISPs identified for ALPPS
8 h after surgery (Figure 1B; Supplementary Data S-II). These
data indicate that the two procedures predominantly differ
quantitatively, not qualitatively. The earlier activation of the Cell
Cycle-pathway (metaphase-anaphase) 8 and 12 h after ALPPS
surgery (Supplementary Data S-III) signifies the initiation of
chromosomal replication and segregation during cell divisions.
It associated with a much earlier cell cycle entrance relative to
standard hepatectomy (Figure 1C; Supplementary Data S-IV),
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TABLE 1 | Comparing the intracellular signaling pathways (ISPs) of standard
(68%) hepatectomy and ALPPS 4h after surgery.
Intracellular signaling pathway PAS (68% Hx) PAS (ALPPS)
Androgen receptor pathway
(gonadotropin regulation)
0.080962033 0.170591759
Androgen receptor pathway (histone
modification)
0.080962033 0.170591759
Androgen receptor pathway (prostate
differentiation and development)
0.080962033 0.170591759
Androgen receptor pathway (sexual
differentiation and sexual maturation at
puberty)
0.080962033 0.170591759
ATM main pathway 0.069585724 0.164331506
ATM pathway (G2_M checkpoint
arrest)
0.192334187 0.758265977
BRCA 1 main pathway −0.01618013 −0.173732307
EGFR main pathway 0.062796782 0.101805817
ErbB family main pathway 0.05751811 0.172579526
GPCR pathway (gene expression) 0.068563364 0.123092979
HGF main pathway 0.062203501 0.112692194
HGF pathway (cell cycle progression) 0.337396472 0. 546430817
Hypoxia pathway EMT 1 0.084001749 0. 691549538
Hypoxia pathway EMT 2 0.084001749 0. 691549538
Hypoxia pathway EMT 3 0.084001749 0. 691549538
Hypoxia pathway EMT 4 0.084001749 0. 691549538
ILK Main Pathway 0.074326641 0.17275502
ILK Pathway (Apoptosis) 0.091947966 0. 169660241
ILK Pathway (Cell adhesion, cell
motility, opsonization)
0.095965334 0. 218655438
ILK pathway (cell cycle proliferation) 0.08622972 0.180086957
ILK pathway (cell migration, retraction) 0.094442075 0.206157845
ILK pathway (cell motility) 0.080839955 0.19368415
ILK pathway (cytoskeletal
reorganization)
0.115000716 0.249836663
ILK pathway (G2-phase arrest) 0.08622972 0.180086957
ILK pathway (induced cell proliferation) 0.197724934 0.186502548
ILK pathway (regulation of intermediate
filaments)
0.106090655 0.23979623
ILK pathway (regulation of junction
assembly of desmosomes)
0.095197611 0.216906194
ILK pathway (wound healing) 0.095197611 0.224489964
IL-10 pathway (stability determination) 0.053478054 1. 848219244
IL-2 main pathway 0.017026437 0. 113993181
lntegrin signaling main pathway 0.067439974 0.145964253
JNK pathway (apoptosis,
inflammation, tumorigenesis, cell
migration)
0.079482132 0.207123801
JNK pathway (insulin signaling) −0.07241052 −0.426061537
MAPK signaling main pathway 0.0519986 0.108187021
MAPK signaling pathway (cell survival,
inflammation, apoptosis,
osmoregulation)
0.212081896 0.229612073
MAPK signaling pathway (gene
expression)
0.091194477 0.149905425
mTOR pathway (actin organization) 0.059587334 0.128667337
(Continued)
TABLE 1 | Continued
Intracellular signaling pathway PAS (68% Hx) PAS (ALPPS)
p53 signaling (negative) main pathway 0.084470457 0.14626007
PAK main pathway 0.034655373 0.117954615
SMAD (negative) main pathway 0.139663741 0.315152085
SMAD (positive) main pathway 0.139663741 0.315152085
TGF beta pathway (SnON degradation) 0.166857414 0.576950547
TGF beta pathway (tumorigenesis) 0.238367734 0. 512365322
TGF beta pathway (tumor suppression) 0.238367734 0. 512365322
TNF (positive) pathway (gene
expression, cell survival)
0.157317821 0.326862624
VEGF pathway (actin reorganization) 0.114882119 0.070794654
Only ISPs with PAS values ≥0.1 are shown. The most significantly affected ISPs (PAS
values ≥ 0.5) are highlighted.
an earlier increased expression of cyclin E1 (Figure 1D) and a
decline of the cell cycle inhibitor p21 mRNA (Figure 1E). To
identify pathways that are most significantly different between
ALPPS and 68% hepatectomy, we performed a more stringent
analysis only including those pathways having PAS values ≥0.1.
We subsequently obtained 47 and 69 affected pathways after
4 and 8 h, respectively. Table 1 displays the PAS values of
these ISPs, demonstrating that the ALPPS procedure affects
the same ISPs as standard hepatectomy, but to a significantly
higher extent. Of particular interest are the highly significant
increased PAS values of the ATM Pathway (G2_M Checkpoint
Arrest), the HGF Pathway (Cell cycle progression), the EMT-
associated hypoxia pathways, and the IL-10 Pathway (Stability
determination). In addition, the three branches of the TGFβ
Pathway and 10 branches of the ILK Pathway were significantly
increased 4 h after ALPPS surgery (Table 1). The same set
of ISPs were retrieved comparing ALPPS-specific pathways to
those significantly affected 32 and 48 h after 68% hepatectomy
(Supplementary Data S-III).
Dissecting ALPPS-Induced Pathway
Activation Profiles
To further elucidate the molecular pathways responsible for
accelerated liver regeneration, hepatic RNA isolated during
the first 12 h after ALPPS, PVL, transection, LLLx, and sham
operation was analyzed. Unsupervised hierarchical clustering
separated the samples into two early groups (≤4 h post OP) and
two late groups (≥8 h post OP). The dendrogram presentation
revealed that ALPPS samples isolated 4 h after surgery grouped
together with all late samples of PVL and ALPPS (≥8 h post OP),
indicating an accelerated biological response after the ALPPS
procedure (Supplementary data S-XII). Principal Component
Analyses confirmed that the major dissimilarities between
surgical procedures occurred 4 h past surgery (data not shown).
In accordance with the expression data, the most distinctive
differences between the groups were observed 4 h after the
surgical procedures were performed. Principal Component
Analyses also confirmed that the major dissimilarities between
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FIGURE 2 | (A) Results of the principal component analysis 0.5, 1, 4, 8, and 12 h after surgery. Green dots, left lateral liver lobectomy (LLLx); Blue dots, Transection;
Red dots, portal vein ligation (PVL); Black dots, ALPPS. (B) Kinetics of the most significant PVL- and ALPPS-induced ISPs over time.
surgical procedures occurred 4 h after surgery (Figure 2A). The
observation that the samples of the same surgical procedures
hardly segregate (colored dots) underlines the excellent
reproducibility of the different surgical procedures. The PAS
data showed that ALPPS surgery significantly affected 72
ISPs, whereas PVL and transection affected 88 and 46 ISPs,
respectively. The kinetics of the most significant PVL- and
ALPPS-induced ISPs are presented in Figure 2B. Next, we
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constructed Venn diagrams to find common and distinctive
ISPs for ALPPS, PVL, and transection. As shown in Table 2,
all surgical procedures involve unique ISPs. After transection,
three unique ISPs are affected: the Glucocorticoid Receptor
Pathway (Gene expression), the Growth Hormone Pathway (Gene
expression), and the IL-2 Pathway (Actin reorganization). The
ALPPS procedure was marked by three unique upregulated
pathways [IGF1R Signaling Pathway (Cell survival), the ILK
Pathway (Induced cell proliferation), the IL-10 Pathway (Stability
determination), and the downregulation of the Interferon
Pathway (Transcription)], whereas the PVL procedure was by
twenty unique ISPs (For all ISPs see: Supplementary Data S-V;
For over-time heatmaps see: Supplementary Data S-VI).
Remarkably, the ISPs affected by ALPPS are not just the sum
of the ISPs affected by PVL plus transection, indicating that
the ALPPS procedure is synergistic rather than additive. To
define time-dependent ALPPS-specific ISP signatures indicated
by the shifted transcriptional landscape, we plotted the PAS
values as a function of time. Four hours after surgery, ten ISPs
presented with a significantly increased PAS value (Figure 3A),
five ISPs were significantly decreased (Figure 3B), whereas 19
ISPs demonstrated unique profiles (Figure 3C).
Identification of ALPPS-Specific
microRNAs
Our dataset contained 73 differentially expressed long non-
coding (lnc)RNA transcripts, of which 60 were identified
as pre-miRNAs (Supplementary Data S-VII). Assuming pre-
miRNA sequences as the precursors of mature miRNAs, we
further analyzed their expression patterns and effects on ISPs.
After removal of possible miRNA-targeted mRNA transcripts
not expressed in the liver, using miRTarBase software we
identified 28 known miRNAs, which together target 2,003
experimentally validated mRNAs (Supplementary Data S-VIII).
How the distribution of miRNA expression patterns changes
over time after ALPPS, PVL, and transection is presented in
Figure 4. We identified six miRNAs, which may serve prominent
roles in the biological processes involved in accelerated liver
regeneration. Mmu-miR 466i-3p and mmu-miR 466i-5p were
exclusively expressed 1 h after ALPPS surgery, whereasmmu-miR
675-3p andmmu-miR 675-5pwere exclusively observed 12 h after
ALPPS surgery. In addition, mmu-miR 3470a and mmu-miR-
3470b were detected 4 h after ALPPS surgery, whereas they first
appeared in the PVL samples 8 h post-surgery.
ISPs Analysis in Human ALPPS
Finally, we assessed to what extent the observations with our
mouse model of ALPPS reflect the biology of accelerated
liver regeneration in humans. Considering the difficulty of
sampling humans’ hepatic samples, we isolated RNA from
liver biopsies taken just before initiating and concluding
the first stage of the ALPPS procedure (4–5 h apart; n = 5).
Again, we built ISPs with normalized RNAseq expression data
using the OncoFinder software and plotted the PAS values of
the 35 most affected ISPs (Figure 5A). The heatmap clearly
demarcated two groups with similar ISP activation patterns
representing the biopsies taken from the occluded lobe and the
TABLE 2 | Activated and repressed ISPs unique for Transection, ALPPS, and PVL
4 h after surgery.
ISPs exclusively in ALPPS PAS
IGF1R signaling pathway (cell survival) 0.09677963
ILK pathway (induced cell proliferation) 0.18650255
IL-10 pathway (stability determination) 1.84821924
Interferon pathway (transcription) −0.47974021
ISPs exclusively in PVL
AKT pathway (cell cycle) 0.09431465
Androgen receptor pathway (cell survival and cell growth) 0.1243162
ATM pathway (cell survival) 0.05295231
cAMP main pathway 0.05587309
cAMP pathway (degradation of cell cycle regulators) −0.04355851
Erythropoeitin main pathway 0.04643793
Hedgehog pathway (repression of Hh, BMP) 0.08050423
HGF Pathway (Anoikis) 0.20617418
HIF1-Alpha main pathway 0.06045947
HIF1Alpha pathway (gene expression) 0.14085828
HIF1Alpha pathway (NOS pathway) 0.16252878
HIF1Alpha pathway (Pyruvate) 0.14085828
HIF1Alpha pathway (VEGF pathway) 0.13205464
IL-10 main pathway 0.27795708
lntegrin signaling pathway (cytoskeleton contraction integrin
modulation cell invasion and migration)
0.12105071
Interferon main pathway 0.03386061
IP3 main pathway 0.03666389
MAPK family pathway (gene Expression) 0.03057693
RAS main pathway 0.04229486
TGF beta pathway (post-transcriptional G1 arrest) 0.13784324
ISPs exclusively in transection
Glucocorticoid receptor pathway (gene expression) −0.01557421
Growth hormone pathway (gene expression) 0.02746121
IL-2 pathway (actin reorganization) 0.4806433
Positive PAS, activated ISPs; Negative PAS values, repressed ISPs. ISPs with PAS.
The most significantly affected ISPs (up and down) are highlighted.
FLR, respectively. Principal Component Analyses confirmed
the major dissimilarities between the two groups (Figure 5B).
The five most activated ISPs in the FLR were identified
as the STAT3 Pathway [G1_to_S_Cell_Cycle_Progression
and the STAT3 Pathway (Anti-Apoptosis)], the JAK-
STAT Pathway (Gene_Expression_via_MYC), the IL-10
Pathway (Stability determination), the Estrogen Pathway
(Vasodilatation), and the Akt-Signaling Pathway (Regulation
of Na+ transport). The five most repressed pathways
were identified as the Glucocorticoid Receptor Signaling
Pathway (Cell_Cycle_Arrest), the Glucocorticoid Receptor
Signaling Pathway (Histone_Deacetylation), the EGF
Pathway (Rab5_Regulation_Pathway), the IGF1R Signaling
Pathway (Glucose_Uptake), and the BRCA1 Pathway
(Base_Excision_Repair). A comprehensive list of all affected
pathways, including the PAS values, can be found in the
Supplementary Data (S-IX). Finally, we compared the ALPPS-
specific pathways identified in our mouse model to those
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FIGURE 3 | PAS values for common ISPs as a function of time after Transection-, PVL-, and ALPPS-surgery. (A) Relative to PVL and Transection, 10 ISPs presented
with a significantly increased PAS value 4 h after ALPPS surgery. (B) Significantly decreased ISPs 4 h after ALPPS surgery (relative to either PVL or transection).
(C) ISPs with a unique profile after ALPPS surgery.
obtained with human liver samples. As demonstrated in
Figure 5C, two of the four ALPPS-specific ISPs of mice are
also upregulated in humans, immediately after ALPPS surgery
step 1 [IGF1R Signaling Pathway (Cell survival) and the IL-10
Pathway (Stability determination)]. In contrast, the ILK Pathway
(Induced cell proliferation) and the IFN main pathway were
not significantly affected. In the human samples, we also
retrieved the ISPs that were highly and significantly enriched
in ALPPS when compared to standard hepatectomy, including
the ATM Pathway (G2_M Checkpoint Arrest), the HGF Pathway
(Cell cycle progression), the EMT-associated hypoxia pathways,
and the ensuing activation of the HIF1Alpha pathway via
Jun_CREB3 (Figure 5C).
DISCUSSION
The novel two-staged hepatectomy ALPPS, which combines
PVL plus a parenchymal liver transection, has gained increasing
interest among liver surgeons. Its importance lies in the
observation that ALPPS induces accelerated liver hypertrophy,
so that hepatectomy can be completed within a very short time
frame (7–10 days post stage 1). Previously, we reported that
the Ihh gene is one of the 50 most upregulated genes 4 h after
ALPPS surgery in mice and present in serum of patients shortly
after the ALPPS procedure (21). We here observed thatHedgehog
signaling is not unique to ALPPS surgery, since it is also activated
during normal liver regeneration after 68% hepatectomy—a
finding in accordance with earlier studies (32). Importantly,
however, hedgehog signaling after 68% hepatectomy was induced
primarily through shh, while ihh is the dominant morphogen
after ALPPS (21).
Our current data demonstrate that ALPPS surgery is unique
in that it induced an earlier activation of the cell cycle,
signified by increased expression of cyclin E1 and a decline
of the cell cycle inhibitor p21. In search of an ALPPS-specific
signature, we observed four ISPs that demarcated the ALPPS
procedure from PVL and transection. After ALPPS surgery,
the IGF1R Signaling Pathway (Cell survival), the ILK Pathway
(Induced cell proliferation), and the IL-10 Pathway (Stability
determination) were significantly enriched, whereas the activity
of the Interferon Pathway (Transcription) was reduced. The
IGF1R signaling pathway for cell survival has been associated
with early wound healing and liver cell proliferation via the
IGF1R/IRS1/ERK axis and activation of the cyclins A1 and
D1. Disrupting hepatic IGF1R signaling has been shown to
significantly impair hepatocyte proliferation in a mouse model
of liver regeneration, and IGFBP-1 null mutants show abnormal
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FIGURE 4 | miRNA expression patterns as a function of time after surgery (Transection, PVL and ALPPS). miRNAs specific for ALPPS, as well as miRNAs expressed
at an earlier time point, are highlighted in bold.
liver regeneration (33). Increased IGF1R signaling may thus
be reflecting an accelerated regeneration process. The integrin-
linked kinase (ILK) is a protein involved in transmitting
extracellular matrix signals and has been associated with the
termination of liver regeneration. Mice lacking hepatic ILK
expression cannot appropriately complete the liver regeneration
process, and DNA synthesis in such mice is prolonged (34). Our
data now indicate that a specific branch of the ILK pathway
is also crucial to the early phase of ALPPS-induced accelerated
liver regeneration, possibly contributing to the early matrix
production. ALPPS surgery is also unique in that it decreased the
IFN-Main Pathway and concomitantly induced a branch of the
IL10 Pathway. Earlier, it was reported that IFN-γ deficiency in
mice enhanced liver regeneration responses (35). In hepatocytes,
IFN-γ activates Stat-mediated signaling, leading to the activation
of p53, which together form transcriptionally active protein
complexes to induce the cell cycle inhibitor p21 (36). The reduced
IFN signaling may thus denote accelerated cell cycle progression
due to diminished p21 activity. Further, the dampening of IFN
signaling implies a role for IFN-γ producing cells, such as T
lymphocytes, NK and NKT cells. In response to surgery-inflicted
injury, these cells may receive signals not to enter the liver or
to silence their activity. The activation of NK and NKT cells
clearly impeded liver regeneration, which also involved IFN-γ
mediated STAT1 signaling (35). The increased activity of the
IL10 pathway is indeed suggestive of such scenarios, since it
functions to diminish inflammatory responses, hence preparing
an environment suitable for augmented regeneration as observed
after ALPPS surgery.
In addition to these ALPPS-specific signaling pathways,
we observed 10 ISPs activated at an earlier time point,
paralleling the hepatic mRNA levels peaking at 4 h post ALPPS
surgery. With nine distinctive branches, the ILK pathways
predominated these shifted ISPs. The integrin-linked kinase
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FIGURE 5 | (A) Hierarchical clustering heatmap based on the analysis of 374 intracellular signaling pathway activation profiles in human liver tissue (occluded lobe
compared to future liver remnant). Red, positive PAS scores; blue, negative PAS scores for a given pathway in a given sample. (B) Results of the principal component
analysis before and after the first step of ALPPS surgery of the human liver samples. (C) PAS values of ALPPS-specific pathways identified in our murine ALPPS
model compared to those obtained with human liver samples.
(ILK) is a PI3-kinase-dependent, serine/threonine protein kinase
that interacts with the cytoplasmic domains of both β1 and β3
integrins, possesses kinase activity, and controls an assortment
of biological activities (37). The wide-ranging functionality of
ILK pathways in numerous processes related to cell proliferation
and tissue remodeling (see: Figure 3A), as well as their early
and increased PAS values after ALPPS surgery, picture ILK as
a plausible key regulator of accelerated liver regeneration. The
earlier activation of one branch of the PAK pathway (myosin
activation), which is also a characteristic feature of ALPPS,
may reflect the above findings, since ILK and PAK1 cross-
regulate each other and together regulate cytoskeletal dynamics.
A function for PAKs has also been established in cell cycle
progression in cancers, in which PAKs are overexpressed or
hyper-activated (38).
Comparing standard hepatectomy with ALPPS surgery,
we demonstrated that 4 h after surgery the two procedures
predominantly differ quantitatively, not qualitatively. The
only ALPPS-specific signature was—as described above—the
suppression of the IFN Main Pathway, which clearly demarcated
ALPPS from standard hepatectomy. The majority of the affected
ISPs demonstrated a low but detectable activity after normal
liver regeneration. After ALPPS surgery, however, the activities
of these ISPs were dramatically increased. Of particular interest
are the four branches of the hypoxia-induced pathway, which are
8.2-fold higher in ALPPS than in standard hepatectomy. Hypoxia
signaling has been implicated in regulating the transition that
is necessary to produce the extracellular matrix but also to
initiate the regenerative capacity of EMT-like liver cells (39).
Although it has been proposed that in situ liver partition
contributes to hypoxia (40), our data explicitly demonstrate
that ligation of the portal vein suffices to induce the hypoxia
pathways (Supplementary Date S-I). Hypoxia of the FLR is thus
an immediate early event after PVL, probably due to an excess of
oxygen-poor blood from the portal vein, and a major trigger for
the accelerated ALPPS-induced regenerative response.
The importance of hypoxia as a driver of liver regeneration is
increasingly being recognized. Although HIFs have traditionally
been in the focus, HIF1A has been reported not to react toward
hypoxia in the liver. Interestingly, HIF1A’s cellular location
was associated with peroxisomes rather than the nucleus upon
exposure of hepatocytes to hypoxia (41). Conceivably, early
changes due to the altered portal flow may provide triggers
(such as activation of Kupffer cells, or the re-organization of
matrix) for regeneration but so far are unproven. When the
parenchyma expands, however, hypoxia develops in analogy to
a growing tumor. After 70%HX, hypoxia leads to HIF2A (but
not HIF1A) activation, which promotes hepatocyte mitosis and
induces VEGF production for the later angiogenic phase (42).
Thus, hypoxia imprints timely order on regeneration, with the
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start of the angiogenic phase coupled to the successful completion
of hepatocyte division. Recently, unspecific activation of HIFs
by ethyl-3,4-dihydroxybenzoate was shown to accelerate PVL
regeneration to ALPPS levels but had no discernible effect on
liver metastases (40, 43). Induction of the HIF pathway may thus
be a first clinical approach to improving liver regeneration after
68% hepatectomy or PVL.
Further, three branches of the TGFβ-pathway, the IL10-
Pathway (stability determination), and the ATM-pathway (G2-
M_Checkpoint_Arrest) are significantly enriched after the
ALPPS procedure. At the molecular level, one of the key
mediators of regenerative responses is the secreted cytokine
transforming growth factor-β (TGFβ) (44). The same branch of
the IL-10-pathway (stability_determination) is again recovered.
Relative to normal hepatectomy, the activity of the ATM main
pathway and its specific branch for G2-M checkpoint arrest
were significantly increased 4 h post ALPPS surgery. The G2-M
DNA damage checkpoint is an important cell cycle checkpoint
ensuring that cells do not initiate mitosis before repairing
damaged DNA after replication. Cells that have a defective G2-
M checkpoint enter mitosis before repairing their DNA, leading
to death after cell division.
Our comprehensive analysis demonstrated that the distinct
surgical procedures underlying ALPPS surgery—PVL and
transection—are discernible by a distinctive set of activated
and repressed ISPs. It also revealed that ALPPS surgery is
not merely an addition of the pathways induced by PVL plus
Transection. Although the molecular mechanism for this
synergism is currently unclear, it might be explained by the
presence and involvement of several unique ALPPS-specific
microRNAs. MicroRNAs (miRNAs) are short, single-stranded
RNAs that modify gene expression at the post-transcriptional
level and are heavily involved in the spatiotemporal control of
gene expression during the entire process of liver regeneration.
The number, nature and level of expressed miRNAs profoundly
depends on the organism studied, the activation status and
microenvironment of cells, as well as other unidentified
factors. In rats and mice, several miRNAs have been linked
to liver regeneration, including miR19a, miR21, and miR214
(45). Here, we recognized 28 precursor transcripts of 28
miRNA present after liver surgery (Transection, PVL, and
ALPPS) and identified four that were uniquely and specifically
enriched after ALPPS surgery.Mmu-miR 466i-3p and mmu-miR
466i-5p were uniquely expressed immediately after ALPPS
surgery, indicating they may underlie the initiation of the
accelerated regeneration process by deactivating the mRNAs
of cell cycle inhibitors. Indeed, miR 466i-3p and mmu-miR
466i-5p intervene with many targets of ISPs that keep the cells
committed and prevent them from preparing for cell cycle
entry, including the PAK Pathway (Actin_Organization), the
p38 pathway (Actin-Cytoskeleton_reorganization), the MAPK
signaling pathways, and the Jnk Pathway (Gene expression
Apoptosis Inflammation_Tumorigenesis_Cell-Migration) (see
Supplementary Data S-X). Likewise, mmu-miR 3470a and
mmu-miR-3470b were uniquely detected 4 h after the ALPPS
procedure and accordingly coincided with the ALPPS-
specific shift described earlier (21). Mmu-miR 675-3p and
mmu-miR 675-5p, both exclusively observed 12 h after ALPPS
surgery, exert a narrower range of biological activities, mainly
silencing anti-proliferative pathways. Indeed, miR-675 and its
precursor long-non-coding RNA, H19, contribute to increased
proliferation, and apoptosis inhibition (46). These ALPPS-
specific miRNAs may cooperate so that the earlier described
ALPPS-specific ISPs become prevalent—unhindered from
competing inhibitory signals and/or ISPs. Also of interest is the
observation that six of the 28 detected miRNAs target the PTEN
gene (mmu-miR-17-5p, mmu-miR-18a-5p, mmu-miR-19a-3p,
mmu-miR-19b-3p, mmu-miR-20a-5p, and mmu-miR-410-
3p), thus enhancing PI3-Kinase/Akt signaling and fatty acid
metabolism. The downregulation of PTEN may fuel liver growth
after hepatectomy due to increased β-oxidation (47).
Comparing the human data to the murine data, we observed
that they have several ISPs in common and that the direction
of change is the same, indicating our ALPPS model reflects
the major changes of accelerated regeneration in humans at the
molecular level. That not all ALPPS-specific ISPs observed in
mice are retrieved in human liver tissue may reflect distinct
kinetics of the liver regeneration process: sufficient regeneration
in our mice model is achieved 2 days post-surgery, while it
takes 7–10 days in humans. Still, the data signify that our
murine ALPPS model—despite differences—may be useful to
gain insight into the molecular background underlying ALPPS-
induced accelerated liver regeneration in humans. Considering
the close match between ISPs in mice and humans, deeper
exploration of our ALPPS model may disclose essential leads
to the development of potential therapeutic strategies targeting
specific ISPs, in particular those that counteract responses of the
immune system.
We realize that our results require further biological
validation, since RNAseq data do not give insights into protein
expression changes or activities of proteins belonging to a specific
pathway. Still, our study provides a comprehensive framework of
the signaling pathways involved in normal and accelerated liver
regeneration, which is now available for further exploration.
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